Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib Plus Ruxolitinib in Myelofibrosis With Suboptimal Response to Ruxolitinib
2020-003415-98Phase 3Terminated
- Sponsor
- Incyte
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Parsaclisib plus ruxolitinib with Placebo plus ruxolitinib (2 arms). Primary endpoint: Proportion of participants achieving ≥ 25% reduction in spleen volume at Week 24. Started Dec 2020; status: terminated.
02
Drugs
parsaclisib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2020-003415-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003415-98.